menu
    • menu
    [{"orgOrder":0,"company":"NaviFUS","sponsor":"NaviFUS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NaviFUS \/ NaviFUS","highestDevelopmentStatusID":"7","companyTruncated":"NaviFUS \/ NaviFUS"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Undisclosed"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Chang Gung Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Chang Gung Memorial Hospital","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Chang Gung Memorial Hospital"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Undisclosed"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NaviFUS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NaviFUS \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by NaviFUS

    Menu

    NaviFUS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Witho...

                            Details : Bevacizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 11, 2024

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfur Hexafluoride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : NaviFUS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblast...

                            Details : Lumason is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Sulfur Hexafluoride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : NaviFUS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NaviFUS Highlights Clinical Trial Data and Device Capabilities at Virtual International Focused Ultrasound Sym...

                            Details : Notable highlights from NaviFUS at the conference include its Epilepsy neuromodulation clinical trial that just finished its safety phase, preliminary progress from its FUS combined with Avastin in rGBM patients clinical trial and other trials.

                            Product Name : Avastin

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 24, 2020

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NaviFUS Launches Clinical Trial of a Combination FUS-Bevacizumab Therapy in rGBM Patients

                            Details : NaviFUS System plus bevacizumab therapy open the blood-brain barrier (BBB) and enhance bevacizumab's efficacy in patients with recurrent glioblastoma (rGBM).

                            Product Name : Avastin

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed

                            NaviFUS

                            Taiwan arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Chang Gung Memorial Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

                            Details : Bevacizumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Chang Gung Memorial Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth